Abstract
The relationships and interactions between foods, the nutrients they contain, and drugs have gained tremendous recognition in the healthcare and medical fields. Certain foods and specific nutrients in foods, if ingested concurrently with some drugs, may affect the overall bioavailability, pharmacokinetics, pharmacodynamics, and therapeutic efficacy of the medications. Furthermore, the therapeutic efficacy of many drugs depends on the nutritional status of the individual. In other words, the presence or absence of some nutrients in the gastrointestinal tract and/or in the body’s physiological system, such as in the blood, can enhance or impair the rate of drug absorption and metabolism resulting in treatment failure. These types of interactions are considered to be nutrient–drug interactions.
There are also drug–nutrient interactions, which mean that the presence of some drugs can significantly affect the food and nutrient metabolism and bioavailability in humans. Medications can alter appetite and taste, and also change the absorption and metabolism of nutrients. This can lead to impaired nutritional status, such as depletion of some minerals and vitamins from the digestive system and sometimes weight problems. The use of certain drugs may affect the GI tract function and lead to a loss of body electrolytes and fluid. Limiting prescription drugs to essential medications for as brief a period as possible and periodic re-evaluations are essential for minimizing adverse reactions. There are many clinical issues and questions regarding drug–nutrient interactions which require further research. However, there is already enough evidence to conclude that some drugs affect nutritional status, sometimes adversely, and that nutritional factors can alter the therapeutic efficacy of some drugs significantly. This chapter describes some of the more common interactions between food and drugs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Thomas JA. Drug–nutrient interactions. Nutr Rev 53:271–282 (1995).
Kirk JK. Significant drug–nutrient interactions. Am Family Physician 51:1175–1182 (1995).
Sultana N, Arayne MS, Furgan H. In vitro availability of lomefloxacin hydrochloride in the presence of essential and trace elements. Pak J Pharm Sci 18(3):59–65 (2005).
Bennett WM. Drug interactions and consequences of sodium restriction. Am J Clin Nutr 65(Suppl 2):678S–681S (1997).
Houlihan CA, Allen TJ, Baxter AL, Panangiotopoulos S, Casley DJ, Cooper ME, Jerums G. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care 25(4):663–71 (2002).
Ameer B and Weintraub RA. Drug interaction with grapefruit juice. Clin Pharmacokine 33:103–121 (1997).
Li P, Callery PS, Gan LS, Balani SK. Esterase inhibition by grapefruit juice flavonoids leading to new drug interaction. Drug Metab Dispos 35(7):1203–08 (2007).
Dresser GK, Bailey DG. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest 33(Suppl 2):10–6 (2003).
Wagner D, Spahn-Langguth H, Hanafy A, Langguth P. Intestinal drug efflux: formulation and food effects. Adv Drug Deliv Review 50(Suppl 1):513–531 (2001).
de Castro WV, Mertens-Talcott S, Derendorf H, Butterweck V. Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci 96(10):2808–17 (2007).
Sica DA. Interaction of grapefruit juice and calcium channel blockers. Am J Hypertens Med 19(7):768–73 (2006).
Kiani J, Imam SZ. Medicinal importance of grapefruit juice and its interaction with various drugs. Nutr J 6:33 (2007).
Karpman HL. Is grapefruit juice harmful? Internal Medicine Alert 23:1–4 (2001).
Noreddin AM, El-Khatib W, Haynes V. Optimal dosing design for antibiotic therapy in the elderly: a pharmacokinetic and pharmacodynamic perspective. Recent Patents Anti-Infect Drug Disc 3(1):45–52 (2008).
Pronsky, Z, Crowe, J. Assessment: Food-Drug Interactions. In: Mahan LK and Escott-Stump S, eds. Krause’s food and nutrition therapy. Philadelphia: Saunders, 2008:432–453.
Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 109(6):2419–23 (2007).
Reese AM, Farnett LE, Lyons RM, et al. Low dose vitamin K to augment anticoagulation control. Pharmacotherapy 25:1746–1751 (2005).
Fork SK, Misita CP, Shilliday BB, et al. Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable International Normalize Ratios. J Thromb Thrombolysis 24:23–27 (2007).
Rombouts EK, Rosendaal FR, Van Der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 5:2043–2048 (2007).
Lamson, DW, Brignall MS. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev 4:304–329 (1999).
Norman H, Butrum R, Feldman E, Heber D, Nixon D, Picciano M, Rivlin R, Simopoulos A, Wargovich M, Weisburger E, Zeisel S. The role of dietary supplements during cancer therapy. J Nutr 133:3794S–3799S (2003).
Chen J, Power KA, Mann J, Cheng A, Thompson LU. Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen. Exp Biol Med 232(8):1071–80 (2007).
Sacco SM, Chen J, Power KA, Ward WE, Thompson LU. Lignan-rich sesame seeds negates the tumor-inhibitory effect of tamoxifen but maintains bone health in a postmenopausal athymic mouse model with estrogen-responsive breast tumors. Menopause 15(1):171–9 (2008).
Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 62(9):2474–2477 (2002).
Messina MJ, Loprinzi CL. Soy for breast cancer survivors: a critical review of the literature. J Nutr 131(11 Suppl):3095S–3108S (2001).
Doerge DR, Chang HC. Inactivation of thyroid peroxidase by soy isoflavones, in vitro and in vivo. J Chromatogr B Analyt Technol Biomed Life Sci 777: 269–79 (2002).
Jabbar MA, Larrea J, Shaw RA. Abnormal thyroid function tests in infants with congenital hypothyroidism: the influence of soy-based formula. J Am Coll Nutr 16:280–2 (1997).
Messina, M et. al. Effects of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients: a review of the relevant literature. Thyroid 16(3):249–58 (2006).
Khanna D, Park GS, Paulus HE, Simpson KM, Elashoff D, Cohen SB, Emery P, Dorrier C, Furst DE. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Arthritis Rheum 52(10):3030–8 (2005).
Chladek J, Simkova M, Vaneckova J, Hroch M, Chladkova J, Martinkova J, Vavrova J, Beranek M. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharamacol 64(4):347–55 (2008).
Genser D. Food and drug interaction: consequences for the nutrition/health status. Ann Nutr Metab 52(Supp 1):29–32 (2008).
Lamy PP. Effects of diet and nutrition on drug therapy. J Am Geriatr Soc 30:S99-S112 (1982).
Akamine D, Filho MK, Peres CM. Drug-nutrient interactions in elderly people. Curr Opin Clin Nutr Metab Care10(3):304–10 (2007).
Alonso-Aperte E, Varela-Moreiras G. Drug –nutrient interaction. Eur J Clin Nutr 54(Supple 1): s69–74 (2000).
Roe DA. Effects of drugs on nutrition. Life Science 15:1219–34 (1974).
Thomas JA and Markovac J. Aspects of neural tube defects: a mini review. Toxic Substances J 13:303–12 (1994).
Hirano T, Yasuda S, Osaka Y, Asari M, Kobayashi M, Itagaki S, Iseki K. The inhibitory effects of fluoroquinolones on L-carnitine transport in placental cell line BeWo. Int J Pharm 351(1–2):113–8 (2007).
Trasobares E, Corbaton A, Gonzalez-Estecha M, Lopez-Colon JL, Pratas P, Olivan P, Sanchez JA, Arroyo M. Effects of angiotensin-converting enzyme inhibitors (ACE i) on zinc metabolism in patients with heart failure. J Trace Elem Med Biol 21(Suppl 1):53–5 (2007).
Atkinson RL. Use of drugs in the treatment of obesity. Ann Rev Nutr 17:383–404 (1997).
O’Rourke M. Smell no evil. Risk Management. 56(6):16 (2009).
Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, Patsch JR, Ebenbichier CF. Metabolic side effects of antipsychotic medication. Int J Clin Pract 61(8):1356–70 (2007).
Treatment recommendations for patients with eating disorders. Am J Psychiat 163(7): 5 (2006).
Drieling T, Biedermann NC, Scharer LO, Strobl N, Langosch JM. Psychotropic drug-induced change of weight: a review. Fortschr Neurol Psychiatr 75(2):65–80 (2007).
Mirenda J and Broyles G. Propofol as used for sedation in the ICU. Chest 108:539–548 (1995).
Navari R. Pharmacological Management of Chemotherapy-Induced Nausea and Vomiting: Focus on Recent Developments Drugs. 69(5): 515–534 (2009).
Adams L, Shepard N, Caruso R, Norling M, et al. Putting Evidence Into Practice®: Evidence-Based Interventions to Prevent and Manage Anorexia. Clin J Oncol Nurs. 13(1): 95–102 (2009).
Filipattos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 31(1):53–65 (2008).
Couris RR, Tataronis GR, Dallal GE, Blumberg JB and Dwyer JT. Assessment of healthcare professionals’ knowledge about warfarin-vitamin K drug-nutrient interactions. J Am Coll Nutr 19:439–45 (2000).
Simpson GM and Gratz SS. Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy volunteer. Clin Pharmacol Therap 52:286–291 (1992).
Nicholls MG. Interaction of diuretics and electrolytes in congestive heart failure. Am J Cardiol 65:17E (1990).
Related Websites
“FDA Public Health Advisory of possible interaction between Hypericum perforatum (St. John’s Wort) and Indinavir, a protease inhibitor used to treat HIV infection” http://www.fda.gov/cder/drug/advisory/stjwort.htm
MedicineNet-Etidronate (Didronel) “Learn how the medication works to strengthen bone and explore its dosage, side effects, and interactions with food and other medicines.”
http://www.FocusOnMedications.com/script/main/art.asp?articlekey=738
MDAdvice.com-Cholestyramine “Description of the antihyperlipidemic agent’s uses, dosage, and side effects includes details about its interactions with foods and medications.” http://www.mdadvice.com/library/drug/drug113.html
Food Medication Interactions “Find a table of contents and sample page of “HIV Medications-Food Interactions Handbook. Resource offers info on food and drug interactions.” http://www.foodmedinteractions.com/
FDA –Zemplar Consumer Information “Medication, also known as paricalcitol, is used to treat high parathyroid hormone levels. Learn about its side effects and drug interactions.” http://www.fda.gov/cder/consumerinfo/druginfo/Zemplar.htm
InteliHealth-Phenelzine Sulfate (Nardil) “Discover how the medication works to relieve depression and investigate its food, drug, and disease interactions. http://www.intelihealth.com/IH/ihtIH/WSIHW000/19689/11728/214201.html?rbrand=Nardil
Thyroid Drugs: Food, Drug and Supplement Interactions “Discover which foods, supplements, and drugs interact with thyroid medications.” http://www.thyroid-info.com/articles/thyroid-drug-faq.htm
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Wunderlich, S.M., Piemonte, J. (2012). Food and Drug Interactions. In: Mozayani, A., Raymon, L. (eds) Handbook of Drug Interactions. Humana Press. https://doi.org/10.1007/978-1-61779-222-9_12
Download citation
DOI: https://doi.org/10.1007/978-1-61779-222-9_12
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-221-2
Online ISBN: 978-1-61779-222-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)